Jonathan Alicea is an assistant editor for HCPLive. He graduated from Princeton University with a degree with English and minors in Linguistics and Theater. He spends his free time writing plays, playing PlayStation, enjoying the company of his 2 pugs, and navigating a right-handed world as a lefty. You can email him at email@example.com.
Brad Glick gives an overview of new and exciting trends in the field of dermatology.
In this final interview segment, Brad Glick, DO, FAAD, Assistant Clinical Professor of Dermatology, Herbert Wertheim College of Medicine, discussed key takeaways in dermatology trends from this past year.
“I think from a therapeutic standpoint, we cannot underestimate the importance of biologics therapy in dermatology,” he said.
He explained that biologic and targeted therapies have been especially crucial for treating conditions such as psoriasis and atopic dermatitis.
Even patients with advanced melanoma have been able to use these therapies, which have ultimately been fruitful in leading them to remission. According to Glick, this advancement—albeit outside the scope of dermatology—has nonetheless proven to be exciting for skin and health care.
And yet, he nonetheless continued to stress the promise of these types of therapies for an array of dermatology-related conditions.
“I can’t say enough about targeted therapies that we have for patients with immune-mediated skin diseases,” he noted. “It has changed the lives of patients with psoriasis, atopic dermatitis, and chronic idiopathic urticaria. And we have many more agents to come.”
Furthermore, he alluded to the increasing importance of telemedicine in healthcare, and the influence it will continue to have on patient care.
Life throughout and beyond the coronavirus disease 2019 (COVID-19) pandemic will continue to feature these types of physician-patient connections, and there is an expectation that the virtual medium can only improve for most specialties, especially dermatology.